XTX Topco Ltd Has $95,000 Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)

XTX Topco Ltd reduced its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 63.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 32,356 shares of the company’s stock after selling 56,540 shares during the quarter. XTX Topco Ltd’s holdings in Sutro Biopharma were worth $95,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Sutro Biopharma by 4.6% during the first quarter. Vanguard Group Inc. now owns 3,022,790 shares of the company’s stock worth $17,079,000 after purchasing an additional 132,790 shares during the period. Kynam Capital Management LP increased its stake in Sutro Biopharma by 28.9% during the 4th quarter. Kynam Capital Management LP now owns 2,001,727 shares of the company’s stock valued at $8,587,000 after purchasing an additional 449,052 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Sutro Biopharma by 30.8% during the second quarter. Acadian Asset Management LLC now owns 1,574,958 shares of the company’s stock worth $4,613,000 after buying an additional 370,705 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in shares of Sutro Biopharma by 1.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,202,431 shares of the company’s stock valued at $5,158,000 after buying an additional 20,263 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Sutro Biopharma by 214.3% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,069,522 shares of the company’s stock valued at $6,043,000 after buying an additional 729,239 shares during the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Price Performance

Shares of NASDAQ:STRO opened at $3.50 on Wednesday. The company has a market capitalization of $286.28 million, a PE ratio of -1.86 and a beta of 1.18. Sutro Biopharma, Inc. has a 1 year low of $2.01 and a 1 year high of $6.13. The business has a fifty day moving average price of $4.03 and a two-hundred day moving average price of $3.94.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.20. The business had revenue of $25.71 million for the quarter, compared to the consensus estimate of $26.28 million. Sutro Biopharma had a negative return on equity of 102.06% and a negative net margin of 73.48%. Sell-side analysts anticipate that Sutro Biopharma, Inc. will post -2.96 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Truist Financial lowered their target price on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 16th. JMP Securities restated a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a report on Monday, September 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a report on Monday, September 16th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $12.13.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.